Trial Profile
Guidelines for Treatment With Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib (Managed Access Program)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 18 Nov 2015
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Bayer
- 13 Nov 2014 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 24 Sep 2012 New trial record